|
TW577875B
(en)
*
|
1997-01-31 |
2004-03-01 |
Shionogi & Co |
Pyrrolidine derivatives with inhibitory activity for phospholipase A2
|
|
JP2003525908A
(ja)
|
2000-03-08 |
2003-09-02 |
ノボ ノルディスク アクティーゼルスカブ |
血清脂質の低下
|
|
DZ3415A1
(fr)
|
2000-08-31 |
2002-03-07 |
Chiron Corp |
Guanidinobenzamides comme mc4-r agonistes.
|
|
ATE348097T1
(de)
|
2001-04-09 |
2007-01-15 |
Chiron Corp |
Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
|
|
EP2243776A1
(en)
|
2001-10-12 |
2010-10-27 |
High Point Pharmaceuticals, LLC |
Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
|
|
WO2003055482A1
(en)
|
2001-12-21 |
2003-07-10 |
Novo Nordisk A/S |
Amide derivatives as gk activators
|
|
WO2003099818A1
(en)
|
2002-05-23 |
2003-12-04 |
Chiron Corporation |
Substituted quinazolinone compounds
|
|
BR0312023A
(pt)
|
2002-06-27 |
2005-03-22 |
Novo Nordisk As |
Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
|
|
JP2007501861A
(ja)
|
2003-05-23 |
2007-02-01 |
カイロン コーポレイション |
Ｍｃ４−ｒアゴニストとしてのグアニジノ置換キナゾリノン化合物
|
|
BRPI0410654A
(pt)
*
|
2003-06-12 |
2006-06-20 |
Novo Nordisk As |
composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
|
|
EP1670815A2
(en)
|
2003-09-30 |
2006-06-21 |
Novo Nordisk A/S |
Melanocortin receptor agonists
|
|
WO2005051391A1
(en)
|
2003-11-19 |
2005-06-09 |
Chiron Corporation |
Quinazolinone compounds with reduced bioaccumulation
|
|
ATE498404T1
(de)
|
2003-12-09 |
2011-03-15 |
Novo Nordisk As |
Regulierung der nahrungspräferenz mit glp-1- agonisten
|
|
JP4834840B2
(ja)
|
2004-01-06 |
2011-12-14 |
ノヴォ ノルディスク アー／エス |
ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
|
|
EP1758856A2
(en)
|
2004-05-04 |
2007-03-07 |
Novo Nordisk A/S |
Indole derivatives for the treatment of obesity
|
|
JP2008501765A
(ja)
|
2004-06-11 |
2008-01-24 |
ノボ ノルディスク アクティーゼルスカブ |
Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
|
|
ES2391776T3
(es)
|
2004-11-22 |
2012-11-29 |
Novo Nordisk A/S |
Formulaciones solubles, estables conteniendo insulina con una sal de protamina
|
|
CN101137631A
(zh)
|
2004-12-03 |
2008-03-05 |
转化技术制药公司 |
杂芳族葡糖激酶激活剂
|
|
RU2499795C2
(ru)
|
2005-07-04 |
2013-11-27 |
Хай Пойнт Фармасьютикалс, ЛЛС |
Антагонисты гистаминовых н3-рецепторов
|
|
US7884210B2
(en)
|
2005-07-14 |
2011-02-08 |
Novo Nordisk A/S |
Ureido-thiazole glucokinase activators
|
|
EP1910317B1
(en)
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
1-amino linked compounds
|
|
ES2393757T3
(es)
|
2005-11-17 |
2012-12-27 |
Eli Lilly & Company |
Antagonistas de receptor de glucagón, preparación y usos terapéuticos
|
|
MX2008011123A
(es)
|
2006-03-28 |
2008-09-30 |
High Point Pharmaceuticals Llc |
Benzotiazoles que tienen actividad de receptor h3 de histamina.
|
|
SG163547A1
(en)
|
2006-05-29 |
2010-08-30 |
High Point Pharmaceuticals Llc |
3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
|
|
ES2377322T3
(es)
|
2006-11-15 |
2012-03-26 |
High Point Pharmaceuticals, Llc |
Nuevas 2-(2-hidroxifenil)benzotiadiazinas útiles para el tratamiento de la obesidad y la diabetes
|
|
US7915299B2
(en)
|
2006-11-15 |
2011-03-29 |
High Point Pharmaceuticals, Llc |
2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
|
|
US20100055071A1
(en)
*
|
2006-11-21 |
2010-03-04 |
Martin Robert Leivers |
Anti-Viral Compounds
|
|
WO2008084044A1
(en)
|
2007-01-11 |
2008-07-17 |
Novo Nordisk A/S |
Urea glucokinase activators
|
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
|
EP2539364A1
(en)
|
2010-02-26 |
2013-01-02 |
Novo Nordisk A/S |
Peptides for treatment of obesity
|
|
EP2552950A1
(en)
|
2010-03-26 |
2013-02-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
WO2012104834A1
(en)
|
2011-02-03 |
2012-08-09 |
Pharmedica Ltd. |
New oral dissolving films for insulin administration, for treating diabetes
|
|
JP2014510739A
(ja)
|
2011-03-28 |
2014-05-01 |
ノヴォ ノルディスク アー／エス |
新規のグルカゴン類似体
|
|
RU2610175C2
(ru)
|
2011-09-23 |
2017-02-08 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
|
SI2986313T1
(sl)
|
2013-04-18 |
2019-09-30 |
Novo Nordisk A/S |
Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
|
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
|
JP2020514365A
(ja)
|
2017-03-15 |
2020-05-21 |
ノヴォ ノルディスク アー／エス |
メラノコルチン４受容体に結合可能な二環式化合物
|
|
WO2019219714A1
(en)
|
2018-05-15 |
2019-11-21 |
Novo Nordisk A/S |
Compounds capable of binding to melanocortin 4 receptor
|
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|
|
CA3219597A1
(en)
*
|
2021-06-23 |
2022-12-29 |
F. Hoffmann-La Roche Ag |
Novel process
|
|
CN116217511B
(zh)
*
|
2023-03-22 |
2024-04-19 |
沈阳药科大学 |
一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用
|